CORRECTING and REPLACING Esperion Therapeutics Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Percent in Hypercholesterolemic Patients with Type 2 Diabetes